How to buy Sutro Biopharma stock

Sutro Biopharma, Inc is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 191 staff and has a trailing 12-month revenue of around 0.00.

Sutro Biopharma share price

Use our graph to track the performance of STRO stocks over time.

Sutro Biopharma shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$7.06 - $28.30
50-day moving average	$21.83
200-day moving average	$20.27
Wall St. target price	$31.83
PE ratio	56.5986
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.44

Buy Sutro Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Sutro Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sutro Biopharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Sutro Biopharma under- or over-valued?

Valuing Sutro Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sutro Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sutro Biopharma's P/E ratio

Sutro Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 57x. In other words, Sutro Biopharma shares trade at around 57x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Sutro Biopharma financials

Revenue TTM	$42.7 million
Gross profit TTM	$-34,239,000
Return on assets TTM	-16.15%
Return on equity TTM	-14.95%
Profit margin	-75.2%
Book value	$7.26
Market capitalisation	$913.1 million

TTM: trailing 12 months

Shorting Sutro Biopharma shares

There are currently 3.5 million Sutro Biopharma shares held short by investors – that's known as Sutro Biopharma's "short interest". This figure is 138.6% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Sutro Biopharma shares can be evaluated.

Sutro Biopharma's "short interest ratio" (SIR)

Sutro Biopharma's "short interest ratio" (SIR) is the quantity of Sutro Biopharma shares currently shorted divided by the average quantity of Sutro Biopharma shares traded daily (recently around 708212.8). Sutro Biopharma's SIR currently stands at 5. In other words for every 100,000 Sutro Biopharma shares traded daily on the market, roughly 5000 shares are currently held short.

However Sutro Biopharma's short interest can also be evaluated against the total number of Sutro Biopharma shares, or, against the total number of tradable Sutro Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sutro Biopharma's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Sutro Biopharma shares in existence, roughly 80 shares are currently held short) or 0.0863% of the tradable shares (for every 100,000 tradable Sutro Biopharma shares, roughly 86 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sutro Biopharma.

Find out more about how you can short Sutro Biopharma stock.

Sutro Biopharma share dividends

We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.

Sutro Biopharma share price volatility

Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $7.06 up to $28.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.7847. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).

Sutro Biopharma overview

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc.

Frequently asked questions

• What percentage of Sutro Biopharma is owned by insiders or institutions?

  Currently 10.676% of Sutro Biopharma shares are held by insiders and 97.496% by institutions.

• How many people work for Sutro Biopharma?

  Latest data suggests 191 work at Sutro Biopharma.

• When does the fiscal year end for Sutro Biopharma?

  Sutro Biopharma's fiscal year ends in December.

• Where is Sutro Biopharma based?

  Sutro Biopharma's address is: 310 Utah Avenue, South San Francisco, CA, United States, 94080

• What is Sutro Biopharma's ISIN number?

  Sutro Biopharma's international securities identification number is: US8693671021

• What is Sutro Biopharma's CUSIP number?

  Sutro Biopharma's Committee on Uniform Securities Identification Procedures number is: 869367102